Verrica Pharmaceuticals (VRCA) announced that its development partner, Torii Pharmaceutical has received approval from the Japanese Ministry of Health, Labour and Welfare, MHLW, for YCANTH, TO-208, for the treatment of Molluscum Contagiosum. Torii became a wholly-owned subsidiary of Shionogi & Co, on September 1, 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRCA:
- Verrica Pharmaceuticals’ Earnings Call Highlights Growth and Strategic Moves
- Verrica Pharmaceuticals: Promising Sales Growth Amid Financial Stability Concerns
- Verrica Pharmaceuticals Sees Revenue Surge in Q2 2025
- Promising Sales Growth and Strategic Initiatives Drive Buy Rating for Verrica Pharmaceuticals
- Verrica Pharmaceuticals Regains Nasdaq Compliance